Resmetirom

REZDIFFRA ® is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH)

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: This indication is approved under accelerated approval based on improvement of MASH and fibrosis.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

What it is used for

This indication is approved under accelerated approval based on improvement of MASH and fibrosis. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Limitations of Use

Avoid use of REZDIFFRA in patients with decompensated cirrhosis.

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in labeling:

Hepatotoxicity
Gallbladder-Related Adverse Reactions

Who should not take it

None.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Resmetirom; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/resmetirom
APA 7th: sofidex. (2026, August 3). Resmetirom. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/resmetirom
AMA 11th: Resmetirom. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/resmetirom

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.